{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(1)"],"submitter":["Gwon Y"],"pubmed_abstract":["<h4>Background</h4>Glioblastoma (GBM) is the most lethal and incurable brain tumor, with limited treatment options. Systemic delivery of many promising drugs has proven inefficacious due to insufficient brain penetrance. Convection-enhanced delivery (CED) enables direct intracranial infusion of high drug concentrations. However, CED is impaired by rapid drug clearance from the brain, which diminishes its therapeutic benefits.<h4>Methods</h4>To develop CED-injectable therapeutics for GBM treatment, two polypeptides, XM147 and XM161, were engineered through tandem recombination of IL4Rα- or IL13Rα2-specific ligands with thermally responsive motifs. XM147-AZDye647 was created by labeling XM147 with the fluorescent dye AZDye647 to study clearance kinetics. Polypeptide-drug conjugates (PDCs), X"],"journal":["Neuro-oncology advances"],"pagination":["vdaf187"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12449142"],"repository":["biostudies-literature"],"pubmed_title":["Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time."],"pmcid":["PMC12449142"],"pubmed_authors":["Kim S","Gwon Y","Jung W","Jeon WB","Shin K","Kim JE","Choi Y","Cheon GJ","Lee Y"],"additional_accession":[]},"is_claimable":false,"name":"Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time.","description":"<h4>Background</h4>Glioblastoma (GBM) is the most lethal and incurable brain tumor, with limited treatment options. Systemic delivery of many promising drugs has proven inefficacious due to insufficient brain penetrance. Convection-enhanced delivery (CED) enables direct intracranial infusion of high drug concentrations. However, CED is impaired by rapid drug clearance from the brain, which diminishes its therapeutic benefits.<h4>Methods</h4>To develop CED-injectable therapeutics for GBM treatment, two polypeptides, XM147 and XM161, were engineered through tandem recombination of IL4Rα- or IL13Rα2-specific ligands with thermally responsive motifs. XM147-AZDye647 was created by labeling XM147 with the fluorescent dye AZDye647 to study clearance kinetics. Polypeptide-drug conjugates (PDCs), X","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan-Dec","modification":"2026-06-03T16:59:57.796Z","creation":"2026-04-29T03:13:05.978Z"},"accession":"S-EPMC12449142","cross_references":{"pubmed":["40980450"],"doi":["10.1093/noajnl/vdaf187"]}}